Until recently, the traditional model of pharmaceutical research had been applied to programs of genetic study, resulting in the many therapeutic agents either under developed or in clinical usage. However, a shift in emphasis is currently taking place towards the so-called "Genome Projects" which enable the identification of gene sequences on a much larger scale and have established gene therapy as a more viable route to treatment. They have also forced pharmaceutical research to its "watershed".
Genomes, Molecular Biology, and Drug Discovery is based on the 7th SmithKline Beecham International Symposium and attempts to bring the continuing advances in modern genome research and molecular biology together with new pharmacological and chemical strategies sharply into focus. It highlights the need for a multi-disciplinary approach in order to direct the wealth of information accumulated towards better community healthcare and close the drug discovery loop.
* Interpreting the Code
* From Gene to Target
* From Target to Therapy
* Conclusions and Challenges
"synopsis" may belong to another edition of this title.
Michael J. Browne graduated in Biochemistry for University College (London, UK) in 1973 and gained Ph.D. in molecular biology from the University of Glasgow in 1976. A keen desire to see rapid advances in molecular biology translated into therapeutic utility lead to work in the pharmaceutical industry, firstly with Beecham Pharmaceuticals (Great Burgh, Surrey,UK) and since 1989 with SmithKline Beecham (New Frontiers Science Park, Essex, UK). Though involved in numerous programs of research, cloning, expression and functionality of receptors, ranging from the single subunit G-protein linked receptors to the more complex cytokine receptors provided a key focus. He is interested not only in drug discovery by high throughput screens and rational medicinal chemical design but also via an understanding of the structure-function relationships of protein agonists and their interactions with the cognate receptor, which can then be exploited via protein engineering to design novel bioactive molecules. More recently the advent of high throughput cDNA sequencing and associated 'genomic strategies' has provided a springboard to discover yet more novel receptor systems of potential therapeutic benefit.
"About this title" may belong to another edition of this title.
Book Description Academic Pr, St Louis, Missouri, U.S.A., 1996. Hardcover. Book Condition: New. Unread and Unmarked. Bookseller Inventory # 012692